Search
Skip to Search Results- 2Veldhoen, Richard
- 1Aburahess, Salah
- 1Akuamoah Boateng, Maxwell
- 1Alqahtani,Hind M
- 1Bekele, Raie Taye
- 1Benesch, Matthew GK
-
Anti-Cancer Mechanism of Trastuzumab via Blocking Nuclear HER2 Function and Epigenetic Mechanism of Resistance
DownloadSpring 2020
HER2 receptor tyrosine kinase (encoded by ERBB2 gene) is overexpressed in approximately 25% of all breast cancer tumors (known as HER2-positive breast cancers). Overexpression of HER2 causes overactivation of downstream receptor tyrosine kinase pathways including PI3K/Akt and MAPK pathways and is...
-
Investigation of BCL-2 interacting killer (BIK) as a breast cancer biomarker and its role in failed apoptosis
DownloadSpring 2019
Breast cancer is the number one cause of cancer-associated deaths in women worldwide. It can be broadly classified into estrogen receptor (ER) positive or -negative subtypes which form the basis of treatment. Despite the therapeutic advancements, more than half a million women annually succumb to...
-
Increased estrogen receptor expression leads to a novel DNA binding signature which differentiates luminal A and luminal B breast cancers
DownloadFall 2018
Eighty percent of all breast cancers are estrogen receptor positive (ER+) and molecular profiling has identified two ER+ subtypes: luminal A and luminal B. The accurate diagnosis of these luminal subtypes is one of the greatest clinical challenges with current gene assays obtaining only 75%...
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Spring 2016
Poxviruses, such as vaccinia virus (VACV) and myxoma virus (MYXV), actively modulate various cellular structures and functions to ensure effective replication and transmission. In the contrary, cells use several restriction mechanisms to mitigate these viruses. This evolutionary relationship is...
-
Living at-Risk for Hereditary Breast Cancer: The Experiences of at-Risk Unaffected Women Who Live in Families Where a BRCA Gene Mutation Could Not be Found
DownloadSpring 2016
Harmful mutations in the breast cancer 1 and 2 genes (BRCA1/2) and other breast cancer susceptibility genes are thought to account for less than 30% of familial breast cancer cases. Many affected women (those with a personal history of breast and/or ovarian cancer) who undergo BRCA1/2 genetic...
-
DDX17 (P72), a Sox2 binding partner, regulates Sox2 to sustain tumorigenic and stem-like properties in a phenotypically distinct subset of estrogen positive breast cancer cells
DownloadSpring 2016
Abstract: Sox2, an embryonic stem cell marker, is involved in the pathogenesis of breast cancer (BC). Sox2 expression is associated with a poor clinical outcome in BC patients. Based on the differential Sox2 transcriptional activity, we have identified the two phenotypically distinct cell...
-
Spring 2016
Tamoxifen is the accepted therapy for patients with estrogen receptor α (ERα)−positive breast cancer. However, clinical resistance to tamoxifen, as demonstrated by recurrence or progression on therapy, is frequent and precedes death from metastases. To improve breast cancer treatment it is vital...
-
Fall 2016
Breast cancer (BrCa) is the most common cancer and the leading cause of cancer-related deaths in women worldwide. Current therapies for BrCa are insufficient to cure metastatic disease and are often associated with debilitating side effects that severely deteriorate the quality of patients’...